The clinical study aims to investigate the effect of the intravenously administrated amylin analogue (pramlintide) on the circulating levels of C-terminal telopeptide of type I collagen (CTX-1) (a marker of bone resorption) and N-terminal propeptide of type I procollagen (P1NP) (a marker of bone formation) in individuals with type 1 diabetes and matched healthy controls during fasting euglycemic conditions.

Start Date12 Feb 2024

Sponsor / Collaborator-

NCT06046417 / RecruitingPhase 2/3IIT

A Randomized, Controlled, Crossover Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Delivery System Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes.

The aim of this clinical trial is to investigate whether a fully automated Lyumjev-and-pramlintide delivery system improves glycemic outcomes in adults with type 1 diabetes. The main question we aim to answer is whether a Lyumjev-pramlintide fully closed loop system improves time in range compared to a hybrid closed loop system with carbohydrate counting. We also aim to find the optimal insulin to pramlintide ratio for glycemic control in the fully automated system.
In this cross-over study, patients will undergo the following three interventions in a random order:
(i) fully automated Lyumjev insulin-and-pramlintide (8 μg/u) (ii) fully automated Lyumjev insulin-and-pramlintide (10 μg/u) (iii) rapid automated Lyumjev insulin-and-placebo with carbohydrate-matched boluses
For all interventions, participants will be required to wear two Ypsomed pumps programmed by our developed EuGlide system.

Start Date30 Nov 2023

Sponsor / Collaborator

McGill University Health Centre

[+1]

NCT05199714 / CompletedNot Applicable

A Randomized, Controlled, Crossover Pilot Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Artificial Pancreas Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes

The investigators aim to assess the glycemic outcomes of a fully automated insulin-and-pramlintide artificial pancreas and a comparator insulin-alone artificial pancreas with carbohydrate matched boluses.

Start Date21 Feb 2022

Sponsor / Collaborator

McGill University Health Center

[+1]

100 Clinical Results associated with Pramlintide Acetate

100 Translational Medicine associated with Pramlintide Acetate

100 Patents (Medical) associated with Pramlintide Acetate

374

Literatures (Medical) associated with Pramlintide Acetate

01 Feb 2024·Computer methods and programs in biomedicine

A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data

Article

Author: Furió-Novejarque, Clara ; Sala-Mira, Iván ; Bondia, Jorge ; Díez, José-Luis

Pramlintide, an amylin analog, has been coming up as an agent in type 1 diabetes dual-hormone therapies (insulin/pramlintide). Since pramlintide slows down gastric emptying, it allows for easing glucose control and reducing the burden of meal announcements. Pre-clinical in silico evaluations are a key step in the development of any closed-loop strategy. However, mathematical models are needed, and pramlintide models in the literature are scarce. This work proposes a proof-of-concept pramlintide model, describing its subcutaneous pharmacokinetics (PK) and its effect on gastric emptying (PD). The model is validated with published populational (clinical) data. The model development is divided into three stages: intravenous PK, subcutaneous PK, and PD modeling. In each stage, a set of model structures are proposed, and their performance is assessed using the Akaike Information Criterion (AIC) and the Bayesian Information Criterion (BIC). In order to evaluate the modulation of the rate of gastric emptying, a literature meal model was used. The final pramlintide model comprises four compartments and a function that modulates gastric emptying depending on plasma pramlintide. Results show an appropriate fit for the data. Some aspects are left as open questions due to the lack of specific data (e.g., the influence of meal composition on the pramlintide effect). Moreover, further validation with individual data is necessary to propose a virtual cohort of patients.

01 Feb 2024·Current opinion in endocrinology, diabetes, and obesity

Treating obesity in type 1 diabetes mellitus – review of efficacy and safety

Review

Author: Freeby, Matthew ; Lane, Kyrstin

Purpose of review:

Obesity is an epidemic in the United States with serious concomitant co-morbid conditions; people living with type 1 diabetes mellitus (T1D) are not immune to the risk either. Weight gain in T1D is likely multifactorial, due to genetic, environmental and treatment-related factors. FDA-approved and other adjunctive weight loss therapies may benefit people living with T1D but there are risks to consider when providing recommendations or prescribing medications.

Recent findings:

We performed a PubMed search of studies assessing clinical outcomes of both approved and off-label medications used in the treatment of type 1 diabetes. Search terms included ‘type 1 diabetes, obesity’ and the following: (1) metformin, (2) pramlintide, (3) glucagon-like peptide-1 (GLP-1) receptor agonists, (4) dual GLP-1 and gastric inhibitory polypeptide (GIP) agonists, (5) sodium-glucose cotransporter-2 (SGLT-2) inhibitors, (6) surgical treatment of obesity, (7) insulin pump, (8) insulin, (9) medical nutrition therapy, (10) diabetes self-management education, (11) exercise, (12) naltrexone-buproprion, (13) orlistat, and (14) phentermine-topiramate.

Summary:

Weight loss treatments provide a wide-range of benefits in reducing both morbidity and mortality in those who are obese. Treatments also have varying adverse effect profiles which may impact T1D treatment. In this review, we aim to summarize study outcomes in people with T1D, including risks and benefits, of on- and off-label weight loss treatments.

01 Feb 2024·Retina (Philadelphia, Pa.)

INTERACTIONS OF METFORMIN AND OTHER MEDICATIONS IN REDUCING THE ODDS OF AGE-RELATED MACULAR DEGENERATION IN A COHORT OF PATIENTS WITH DIABETES

Article

Author: Skondra, Dimitra ; Khanna, Saira ; Shaw, Lincoln ; Parvar, Seyedeh P ; Hyman, Max J ; Hariprasad, Seenu ; Blitzer, Andrea ; Flores, Andrea ; Ham, Sandra ; Soo, Jackie

Purpose::

A previous study from our group demonstrated protective effects of the use of metformin in the odds of developing age-related macular degeneration (AMD). This is a subgroup analysis in a cohort of patients with diabetes to assess the interaction of metformin and other medications in protecting diabetic patients against developing AMD.

Methods::

This is a case-control analysis using data from the Merative MarketScan Commercial and Medicare databases. Patients were 55 years and older with newly diagnosed AMD and matched to controls. We performed multivariable conditional logistic regressions, which adjusted for known risk factors of AMD and tested multiple interaction effects between metformin and 1) insulin, 2) sulfonylureas, 3) glitazones, 4) meglitinides, and 5) statins.

Results::

The authors identified 81,262 diabetic cases and 79,497 diabetic controls. Metformin, insulin, and sulfonylureas demonstrated independent protective effects against AMD development. Sulfonylureas in combination with metformin demonstrated further decreased odds of AMD development compared with metformin alone. The other medication group (exenatide, sitagliptin, and pramlintide) slightly increased the odds of developing AMD when taken alone, but the combination with metformin alleviated this effect.

Conclusion::

The authors believe that their results bring them one step closer to finding an optimal effective hypoglycemic regimen that also protects against AMD development in diabetic patients.

News (Medical) associated with Pramlintide Acetate

17 Apr 2024

·www.biospace.com

Xeno Biosciences Announces New CEO and Financing - April 17, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today a change in executive leadership as of September 2023, and the completion of an additional financing round in February of 2024. This financing of $1.15M will fund a Phase 1b trial of the company’s lead compound, Xen-101, in obese individuals. The trial is expected to have top line results by the end of the year. The new president and CEO, Dennis D. Kim, MD, MBA, has 25 years of obesity and metabolic drug development expertise experience and has brought multiple obesity and metabolic disease drugs to the clinic and to market, including Byetta® (exenatide), Symlin® (pramlintide), Contrave® (bupropion/naltrexone), and seladelpar. He has been involved in numerous IPO’s/secondary offerings and has been the chief medical officer of multiple public companies, most recently at CymaBay Therapeutics, where he oversaw the design and execution of seladelpar Phase 3 Pivotal Program. “I’m excited to be spearheading the development of Xeno’s new oral obesity drug which has been shown to have high tolerability in initial Phase I trial and has a novel mechanism of action.” said Dr. Dennis Kim. “I have dedicated my career to this area of science and medicine. After many years of development, I am truly gratified to see obesity pharmaceuticals as having the potential to impact the lives of billions of people around the world. There is a strong unmet need for a drug with the pro Xen-101 and I look forward to our Phase 1b clinical trial results in obese adults in the near future.” “Dennis has an extraordinary depth of knowledge and is highly respected in the obesity field; I could not imagine anyone more perfect to lead our company,” said Jeff Arnold, Chairman and a Director at Xeno since 2017. “We are delighted that he has decided to join us and lead this exciting project.” For more information about Xeno Biosciences please contact Dr. Dennis Kim at dk23@xenobiosciences.com. About Xeno Biosciences Inc. Xeno Biosciences Inc. is a privately held drug development company dedicated to finding safe and effective treatments for obesity and metabolic diseases. Xeno is advancing its lead development candidate, XEN-101, to address the unmet need for an effective, well-tolerated, orally administered obesity treatment. With a new understanding of the underlying mechanism of action of Roux-en-Y Gastric Bypass Surgery (RYGB), Xeno has developed a substitute for gastric bypass in a daily oral pill. XEN-101 has been shown to have wide safety margins and high tolerability in initial clinical trials. Dennis D. Kim, MD, MBA Dr. Dennis Kim is a scientist and a physician executive who brings 25 years of clinical research and biopharmaceutical industry experience to Xeno Biosciences. Dr. Kim served in a variety of senior executive positions in the industry, most recently as Chief Medical Officer at CymaBay, Emerald Biosciences, and Zafgen, Inc., as well as at Orexigen Therapeutics as the Senior Vice President of Medical Affairs. He also held various senior management positions at Amylin Pharmaceuticals, Inc. for over 7 years, including Executive Director of Corporate Strategy and Program Medical Lead for the development and commercialization of Byetta® (exenatide) for the treatment of type 2 diabetes. Dr. Kim completed his fellowship in Endocrinology/Metabolism at the University of California, San Diego (UCSD) School of Medicine during which time he investigated the pathophysiology of diabetes and metabolic syndrome. He is extensively published in top peer-reviewed medical and scientific journals with over 50 publications to his name. Dr. Kim also received an MBA degree with honors from UCSD Rady School of Management with an emphasis on biotech structure and strategy. The securities sold in the aforementioned private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the aforementioned shares. In addition, this press release contains certain forward-looking statements regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and the company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. View source version on businesswire.com: Contacts Dr. Dennis Kim dk23@xenobiosciences.com Source: Xeno Biosciences Inc. View this news release online at:

Executive ChangePhase 1Phase 2

01 Dec 2023

·www.businesswire.com

Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery

SHANGHAI & BOSTON--( BUSINESS WIRE )--Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery. The financing round was led by Chengwei Capital. The company also announced key appointments to its leadership team, including Kerry L. Blanchard, MD, PhD, Co-founder, Chairman and Chief Executive Officer; Ved Srivastava, PhD, Chief Technology Officer; and Xiang Ye, PhD, Chief Scientific Officer. “Perpetual Medicines is capitalizing on recent advances in computational modeling based on artificial intelligence, deep learning and machine learning that enable access for the first time to the enormous, untapped peptide chemical space for drug discovery,” said Dr. Blanchard. “We have built an integrated platform that allows us to virtually iterate through millions of peptide sequences using physics-based computations to predict binding and drug-like properties followed by integration with experimental data to discover and optimize product candidates. This approach has the potential to accelerate peptide drug discovery, reduce cost, and increase the quality of drug candidates. With the financing the company will advance our most advanced program to the clinical stage and continue to build our preclinical portfolio of projects in oncology, autoimmunity, and metabolic diseases.” Dr. Blanchard noted that peptide therapeutics have become the most rapidly growing sector of the pharmaceutical industry with predicted sales exceeding $140 billion 1 /year by 2030. “Peptides fill the gap between small molecule drugs and therapeutic antibodies,” he said. “They are large enough and selective enough to block interactions between proteins inside and outside cells. These attributes, along with access to vastly expanded chemical space, will open new target classes and allow us to attack previously undruggable pathobiology.” Senior Management Team Named Perpetual has assembled a highly experienced senior management team, who have collectively accrued more than 120 years of drug hunting experience and have helped lead the development of more than ten marketed peptide-based therapeutics. The senior management team includes: Kerry L. Blanchard, MD, PhD – Co-Founder, Chairman and Chief Executive Officer. Dr. Blanchard is an experienced entrepreneur who has built deep R&D leadership and management experience over a 40+ year career. He was instrumental in the discovery of four marketed products, oversaw the clinical development and approval of more than 25 new medicines in China, and led two successful IPOs on the Hong Kong stock exchange. He has deep experience in developing peptide therapeutics from vancomycin and colistins to incretins. Prior to co-founding Perpetual Medicines, he was CEO of Everest Medicines. Previously, he was Chief Scientific Officer at Innovent, and he held several senior R&D leadership positions at Eli Lilly and Company over a nearly 18-year career, most recently as Senior Vice President China Drug Development. Prior to his industry career, he spent nearly 20 years in academic roles at LSU Health Science Center and Harvard Medical School. Ved Srivastava, PhD, Chief Technology Officer – Dr. Srivastava brings to Perpetual Medicines more than 25 years of experience in the discovery and development of peptide therapeutics. He joined Perpetual from Aktis Oncology. He was instrumental in the development of several peptide-based drugs, including Byetta™, Symlin™ and Bydureon™. He has served as Head of Peptide Chemistry at both GlaxoSmithKline and Amylin Pharmaceuticals. He was also a co-founder at Phoundry Pharma and Vice President of Chemistry at both Intarcia and Aktis. Ved is a former president of the American Peptide Society (APS). Xiang Ye, PhD – Chief Scientific Officer. Dr. Ye’s experience includes a more than 22-year career at Eli Lilly, where he focused on drug research and translational medicine. During his career, he led the discovery and development of eight clinical candidates, including a globally approved cancer drug, Verzenio® (abemaciclib). He joined Perpetual Medicines from Risen Pharmaceuticals, where he served as Chief Scientific Officer. Prior to Risen, he also served as Chief Scientific Officer at Ionova Life Sciences. About Chengwei Capital Chengwei Capital is a Shanghai-headquartered venture capital firm specialized in investing in high-end technology and innovative startups. It is one of the earliest venture capital firms in China and launched China’s first evergreen fund in 2004. Chengwei Capital currently has over USD $3 billion in NAV under management. About Perpetual Medicines Perpetual Medicines is a fully integrated computational peptide therapeutics company that aims to build a next-generation peptide drug discovery engine. The company’s platform combines the predictive power of leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space. The platform is designed to address previously undruggable targets, accelerate discovery and enhance the quality of peptide drug candidates. The company has operations in Shanghai, China and Boston, MA. Learn more at: perpetualmeds.com ________________________________ 1 Evaluate Pharma

Executive Change

06 Oct 2022

·www.biospace.com

Clinical Catch-Up: Adocia, Allecra Therapeutics & Aldeyra Therapeutics

Adocia, Allecra Therapeutics and Aldeyra Therapeutics are ending the week with promising results from their respective clinical trials on hard-to-treat diseases. Continue reading below. Adocia Anti-Obesity Candidate Fares Well vs Humalog In Phase II Study New data released Thursday from Adocia's Phase II trial of M1Pram in obese people with Type I Diabetes demonstrated the drug's ability to deliver significant weight loss results versus Humalog. M1Pram, a combination of M1 insulin and pramlintide, is in a regular insulin pen form, and Adocia has a patent for coformulation up to 2038. Pramlintide is an FDA-approved amylin analog used as an insulin adjunct in people with type I and type II diabetes and can improve glycemic control, weight loss and general well-being. Post-hoc analyses of the M1Pram study showed that those who used the combination saw a reduction in body mass index by 5.56 kg at week 16 compared to a decrease of only 0.57 kg in those who took Humalog. Weight loss also did not plateau by the end of the study period. In terms of glycemic control, M1Pram offered results "as good as gold standard mealtime insulin," the report stated. The drug also reduced the participants' daily dose of prandial insulin by 21%. Adocia is reportedly seeking partnership opportunities to further develop M1Pram's potential. Allecra's Proposed cUTI Drug Combo Meets Superiority Endpoint In Phase III Allecra Therapeutics' first full analysis of the completed Phase III ALLIUM trial of cefepime/enmetazobactam released Wednesday demonstrated the combination drug candidate's effectiveness in treating people with complicated urinary tract infections (cUTIs). Results published in the Journal of the American Medical Association (JAMA) showed that cefepime/enmetazobactam met non-inferiority and superiority criteria when it was compared to piperacillin/tazobactam in the primary outcome of microbiological eradication and clinical cure. The primary outcome was achieved in 79.1% of the cefepime/enmetazobactam group versus 58.9% in the piperacillin/tazobactam group. Treatment-emergent adverse events cropped up, but most were mild to moderate. Allecra is currently working with ADVANZ PHARMA to commercialize cefepime/enmetazobactam in the U.K., Switzerland, Norway and the European Union and will complete submission for marketing authorization by the end of the year. Allecra is seeking commercialization partners in the U.S. and working on regulatory submissions. Aldeyra Retinal Disease Drug Achieves Primary Endpoint, No Safety Concerns Aldeyra Therapeutics announced Thursday that its proposed treatment for proliferative vitreoretinopathy (PVR) achieved the primary endpoint of numerical superiority versus routine surgical care in preventing retinal detachment. ADX-2191 (methotrexate injection, USP) is a sterile, non-compounded intravitreal formulation designed to prevent or treat retinal diseases. The FDA gave ADX-2191 an orphan drug designation for the prevention of proliferative vitreoretinopathy, and the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. Part I of Aldeyra's Phase III GUARD trial was conducted over six months, with 68 patients receiving ADX-2191 and 38 receiving a routine surgical intervention. Although secondary or exploratory endpoints were not met, the drug exhibited superiority in reducing the retinal detachment rate, hypotony, complete retinal detachment by six months, epiretinal membrane formation and macular attachment. Given these results, Aldeyra plans to hold a Type C meeting with the U.S. FDA by the first half of 2023 to discuss completing clinical development activities for the drug.

Orphan Drug

100 Deals associated with Pramlintide Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D05595	Pramlintide Acetate	A10BX05	DB01278

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	US	AstraZeneca AB	16 Mar 2005
Diabetes Mellitus, Type 2	US	AstraZeneca AB	16 Mar 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Insulin-Dependent, 2	Phase 3	US	AstraZeneca PLC	01 Apr 2003
Obesity	Phase 2	US	AstraZeneca PLC	01 Aug 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed	Not Applicable	Diabetes Mellitus, Type 1	-	ADO09	otdcjuogxh(ljbgevkofb) = uodeuwonik yezwtoymyq (friejlqanu ) View more	-	12 Jan 2023
				Insulin aspart	otdcjuogxh(ljbgevkofb) = dwipdibocc yezwtoymyq (friejlqanu ) View more
NCT01841359 (CTgov)	Phase 4	Hypoglycemia \| Stomach Diseases	22	Pramlintide (Baseline (Prior to Pramlintide Treatment) Mixed Meal #1)	oijygjwdhy(lwwhkivbxq) = ssmpmazbfp otbayacyba (ucgluwxuqp, dtqyacoznb - crihwfjiky) View more	-	26 May 2022
				Pramlintide (Pramlintide - Mixed Meal #2)	oijygjwdhy(lwwhkivbxq) = meabojuhns otbayacyba (ucgluwxuqp, austdygbja - xnqpknblym) View more
NCT00690235 (CTgov)	Phase 4	Diabetes Mellitus \| Schizoaffective disorder \| Schizophrenia ... View more	33	Pramlintide (Pramlintide)	gibiucnpme(scdiyddvbf) = qcrdvkdupn jvonvrrklf (gpfpwqxaau, zqthjumvjc - vgduvtydye) View more	-	16 Nov 2018
				Placebo (Placebo)	gibiucnpme(scdiyddvbf) = efjxfpahhc jvonvrrklf (gpfpwqxaau, bkpfhrvvtz - okkkyoboil) View more
NCT02500979 (CTgov)	Phase 1	Diabetes Mellitus, Type 1	34	Insulin (Placebo & Regular Insulin)	mlmhrknmct(cfrdravfnr) = ikadrhjclb vwyllxruco (hzcabsudwy, huohkykadg - myifkatqdc) View more	-	02 Nov 2018
				Insulin+Pramlintide (Pramlintide & Regular Insulin)	mlmhrknmct(cfrdravfnr) = jgkqxwwpea vwyllxruco (hzcabsudwy, oxrbvpgabw - wbeqiebufd) View more
NCT02500979 (Pubmed \| Diabetes Care)	Phase 1	Diabetes Mellitus, Type 1	34	Pramlintide	gnmhjrpllv(llhmnhydbp) = mhvurqtfqs xrdvdxrfqb (cfgjpxrhgh )	-	01 Nov 2018
				Placebo	gnmhjrpllv(llhmnhydbp) = semnnaulwg xrdvdxrfqb (cfgjpxrhgh )
EASD2018	Not Applicable	-	-	BC Pram Ins	gcwsdenskd(yppnsghvna) = 0.45 [0.20; 1.05] sodyiainrs (hdocobtxdg ) View more	Positive	02 Oct 2018
				Humulin
NCT00442767 (CTgov)	Phase 4	Diabetes Mellitus, Type 1 \| Hyperglycemia	8	Insulin (Rapid Acting Insulin Therapy - Before Meal)	wrranweahf(uxgicidmzq) = qhfqmbbzcd qtdcsjmmcn (onhzpygjwm, hmhwifekba - sxuyjkcyxc) View more	-	10 Jul 2018
				Insulin+Pramlintide (Pre-meal Pramlintide and Post-meal Insulin Therapy)	wrranweahf(uxgicidmzq) = zihtzhhpqd qtdcsjmmcn (onhzpygjwm, yjwfkdupvj - rmrbhnnhhc) View more
NCT01269047 (CTgov)	Phase 4	Diabetes Mellitus, Type 1 \| Hyperglycemia	37	Insulin (Insulin Monotherapy)	ntlohvrchn(caaekwzqxn) = vaueqluqun ofdurvkjac (wvobjgoqnk, pvcioawolz - tcjhkjuvqz) View more	-	08 Feb 2018
				Pramlintide (Pramlintide + Insulin Group)	vdxbootyid(jjizpsizxi) = ercptwrjct ubcydmtzvo (tutyfzgypg, cgygosephn - bjwtoqewch) View more
NCT00673387 (CTgov)	Phase 2	Obesity	636	pramlintide acetate+metreleptin (Pramlintide 180 mcg + Metreleptin 2.5 mg)	hcdmlqvwsg(jqmeujoopi) = zsskjperea ulbygctscl (fhotheultp, xuackamtqd - mbrgjljiht) View more	-	14 Nov 2013
				pramlintide acetate+metreleptin (Pramlintide 180 mcg + Metreleptin 5.0 mg)	hcdmlqvwsg(jqmeujoopi) = ewfcpwnpuc ulbygctscl (fhotheultp, xvlnxdvbxi - ppdioccqcy) View more
NCT00108004 \| NCT00042458 (Pubmed \| Postgrad Med)	Not Applicable	Diabetes Mellitus, Type 1	-	Pramlintide	rdskvnaawc(khxbtyhgmh) = Short-lived nausea, primarily mild to moderate in intensity, was the most common adverse event associated with pramlintide therapy ednftuzqsz (ehqmxsbpxa )	-	01 May 2013
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis